bf/NASDAQ:ALRN_icon.jpeg

NASDAQ:ALRN

Aileron Therapeutics

  • Stock

2.11

+9.33%

0.18

USD last updated 13/08 01:59:42

Last Close

1.93

10/01 21:00

Market Cap

66.06M

Beta: 2.01

Volume Today

63.39K

Avg: 53.55K

PE Ratio

−1.68

PFCF: −1.64

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -2-1.5-1-0.52020-12-312022-05-052023-11-072024-04-152024-11-08

    Revenue (Estimate*)

    20K40K60K80K100K120K140K2020-12-312022-05-052023-11-072024-04-152024-11-08

    *Estimate based on analyst consensus